<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141176</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03014-51</org_study_id>
    <nct_id>NCT04141176</nct_id>
  </id_info>
  <brief_title>Obstructive Sleep Apnea Syndrome: Evaluation of the Efficacy of Sleepinnov© (Spiri+) Continuous Positive Airway Pressure Device</brief_title>
  <acronym>Spiri+</acronym>
  <official_title>Evaluation of the Efficacy of Sleepinnov© (Spiri+) Continuous Positive Airway Pressure Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sleepinnov Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICUREsearch</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sleepinnov Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous Positive Airway Pressure (CPAP) is the reference treatment of patients suffering
      from Obstructive Sleep Apnea Syndrome (OSAS).This device functions as a pneumatic stent that
      stabilizes the upper airway, prevents periodic collapses during sleep.The correction of
      abnormal respiratory events during sleep allows improvement of symptoms related to OSAS and
      restores quality of life.The purpose of this study is to validate the efficacy of a new CPAP
      brand developed by Sleepinnov©.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea syndrome (OSAS) is characterized by the repetitive occurrence of
      partial or complete pharyngeal obstructions during sleep.Continuous Positive Airway Pressure
      (CPAP) is the first line treatment of OSAS.

      The aim of the prospective monocentric two steps pilot study SPIRI+ is to validate the
      efficacy of a new CPAP brand developed by Sleepinnov©.

        -  the first step will validate the capability of the algorithm to appropriately detect of
           abnormal repiratory events during sleep.the metrics will be a comparison of the total
           number of events detected by the CPAP Sleepinnov© with data arising from a concurrent
           polysomnography.

        -  the second step will check overall clinical efficacy of the new CPAP device by assessing
           the percentage of OSAS with an index of residual events below 10 and 5 per hour.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">April 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>It's a prospective, open, monocentric study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Validation of algorithm detection of respiratory events</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of the total number of events detected by the CPAP Sleepinnov© with data arising from a concurrent polysomnography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Validation of overall clinical efficacy</measure>
    <time_frame>baseline</time_frame>
    <description>Percentage of OSAS with an index of residual events below 10 and 5 per hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1:</measure>
    <time_frame>baseline</time_frame>
    <description>Compare the different types of events detected by the Spiri + CPAP algorithm to the concomitant respective indices scored during concurrent</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Spiri+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>new CPAP device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spiri+</intervention_name>
    <description>CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.</description>
    <arm_group_label>Spiri+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed and untreated Obstructive sleep apnea syndrome (IAH &gt;15/hour) with an
             indication of treatment with CPAP

          -  Patients who have given their informed written consent

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients not affiliated to the French social security system or equivalent

          -  Patient deprived of liberty by judicial or administrative decision

          -  Patients under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud Tamisier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Louis Pépin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Destors, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien Baillieul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Argod</last_name>
    <phone>+33 4 76 37 05 79</phone>
    <phone_ext>+33</phone_ext>
    <email>jerome.argod@sleepinnov.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne Loiodice</last_name>
    <phone>+33 4 76 76 84 74</phone>
    <phone_ext>+33</phone_ext>
    <email>cloiodice@chu-grenoble.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, Hamilton GS, Dharmage SC. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev. 2017 Aug;34:70-81. doi: 10.1016/j.smrv.2016.07.002. Epub 2016 Jul 18. Review.</citation>
    <PMID>27568340</PMID>
  </reference>
  <reference>
    <citation>Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, Lavie L, Pépin JL. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015 Jun 25;1:15015. doi: 10.1038/nrdp.2015.15. Review.</citation>
    <PMID>27188535</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Continuous positive airway pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

